A POST‐MARKETING SURVEILLANCE STUDY OF 703 PATIENTS TREATED WITH CHIDAMIDE FOR PERIPHERAL T‐CELL LYMPHOMA (PTCL) IN CHINA. HDAC STUDY GROUP OF UNION FOR CHINA LYMPHOMA INVESTIGATORS (UCLI)

J. Ma; J. Zhu; Y.K. Shi; H.Q. Huang; W.Q. Jiang; W.Y. Li; J.H. Wang; W. Xu; M. Hou; Z.M. Jin; T. Liu; P. Liu; W.L. Zhao; H.L. Zhang; H.Y. Yang; X. Zhang; J. Jin; Z.M. Li; L.G. Qiu; M. Dong; X. Wang; J.F. Zhou; J.Z. Shen; X.Q. Chen; Y.Q. Song

doi:10.1002/hon.2438_114

登录

免费注册

赞收藏引用

科研之友

微信

新浪微博

Facebook

分享链接

A POST‐MARKETING SURVEILLANCE STUDY OF 703 PATIENTS TREATED WITH CHIDAMIDE FOR PERIPHERAL T‐CELL LYMPHOMA (PTCL) IN CHINA. HDAC STUDY GROUP OF UNION FOR CHINA LYMPHOMA INVESTIGATORS (UCLI)

作者：J. Ma; J. Zhu; Y.K. Shi; H.Q. Huang; W.Q. Jiang; W.Y. Li; J.H. Wang; W. Xu; M. Hou; Z.M. Jin; T. Liu; P. Liu; W.L. Zhao; H.L. Zhang; H.Y. Yang; X. Zhang; J. Jin; Z.M. Li; L.G. Qiu; M. Dong; X. Wang; J.F. Zhou; J.Z. Shen; X.Q. Chen; Y.Q. Song

来源：Hematological Oncology, 2017, 35: 250-251.

DOI：10.1002/hon.2438_114